title: MAGE: the spell is broken.
abstract: The success of immunotherapy in Hodgkin lymphoma is hampered partly by limited expression of tumor-specific antigens in the malignant cells. One strategy to increase tumor immunogenicity may be to enhance the expression of Hodgkin lymphoma-specific antigens such as MAGE-A4 using epigenetic-modifying drugs in combination with cancer testis antigen-specific immunotherapy.
authors: Katayoun
authors: K
authors: Rezvani
mesh_terms: D000951:Antigens, Neoplasm / Q000378:metabolism*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077209:Decitabine; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D009363:Neoplasm Proteins / Q000378:metabolism*; D013601:T-Lymphocytes / Q000637:transplantation*
chemical_list: D000951:Antigens, Neoplasm; D000964:Antimetabolites, Antineoplastic; C095204:MAGEA4 protein, human; D009363:Neoplasm Proteins; D000077209:Decitabine; D001374:Azacitidine